BonGeo Pharmaceuticals Inc.
BonGeo Pharmaceuticals Inc., headquartered in the United States, is a prominent player in the biopharmaceutical industry, specialising in innovative therapies for chronic diseases. Founded in 2010, the company has made significant strides in research and development, focusing on areas such as oncology and autoimmune disorders. With a commitment to advancing healthcare, BonGeo Pharmaceuticals offers a unique portfolio of biologics and small molecule drugs that stand out for their efficacy and safety profiles. The company has achieved notable milestones, including successful clinical trials and strategic partnerships that enhance its market position. Recognised for its dedication to quality and innovation, BonGeo Pharmaceuticals continues to expand its operational reach, aiming to improve patient outcomes globally while maintaining a strong presence in the US and other key markets.
DitchCarbon Score
How does BonGeo Pharmaceuticals Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
BonGeo Pharmaceuticals Inc.'s score of 3 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
BonGeo Pharmaceuticals Inc.'s reported carbon emissions
BonGeo Pharmaceuticals Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that BonGeo Pharmaceuticals may not have established formal commitments to reduce its carbon footprint or engage in climate initiatives at this time. As the pharmaceutical industry increasingly prioritises sustainability, it will be essential for BonGeo Pharmaceuticals to consider developing and communicating its climate commitments to align with industry standards and expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
BonGeo Pharmaceuticals Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
